VGT vs XBI
Vanguard Information Technology ETF vs SPDR S&P Biotech ETF
- • VGT has the lower expense ratio at 0.09% vs 0.35% for XBI.
Side-by-side metrics
| Metric | VGT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.36% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $169.25B | $10.73B |
YTD return | 22.83% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.44 | 1.10 |
P/E ratio | 35.52 | — |
Last price | $118.19 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
VGT top holdings
| NVDA | NVIDIA Corp | 16.78% |
| AAPL | Apple Inc | 15.26% |
| MSFT | Microsoft Corp | 9.87% |
| AVGO | Broadcom Inc | 4.49% |
| MU | Micron Technology Inc | 4.19% |
| AMD | Advanced Micro Devices Inc | 3.20% |
| INTC | Intel Corp | 1.95% |
| CSCO | Cisco Systems Inc | 1.85% |
| LRCX | Lam Research Corp | 1.55% |
| ORCL | Oracle Corp | 1.45% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VGT
VGT (Vanguard Information Technology ETF) is US technology sector stocks. Managed by Vanguard, the fund carries $169.2B in assets under management, an expense ratio of 0.09%, a dividend yield of 0.36%. Its largest holding is NVIDIA Corp (NVDA), which represents 16.8% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 0.1%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.